Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218378

SCHEMBL23218378

SCHEMBL23218378

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C(O)C(F)(F)F)oc2ccc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ MTNR1B P49286 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ HPGD P15428 3/20 0.34
▸ ALOX5 P09917 2/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ ANO1 Q5XXA6 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ GABRP O00591 1/20 0.33
▸ GABRD O14764 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB1 P18505 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853040 0.90 TSHR (0.40) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23218140 0.90 TSHR (0.40) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL29853107 0.90 TSHR (0.40) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23218770 0.90 TSHR (0.40) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23219031 0.89 TSHR (0.41) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL29853161 0.89 TSHR (0.41) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23218346 0.88 TBXAS1 (0.36) TSHRMAPTKDM4EALDH1A1HPGD
SCHEMBL29852858 0.86 TSHR (0.41) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23218415 0.86 TSHR (0.41) TSHRMAPTMTNR1BKDM4EALDH1A1
SCHEMBL23218119 0.86 TSHR (0.47) TSHRMAPTMTNR1BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TSHR 1199/4885MAPT 4793/4885MTNR1B 3580/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TSHR 3148/4885MAPT 3561/4885MTNR1B 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.